Inhibitors of phosphodiesterase 4 (PDE 4): A new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

(2014) P.H. Schafer et al.   CELLULAR SIGNALLING

Apremilast: First Global Approval

(2014) Raewyn M. Poole et al.   DRUGS

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

(2013) Vibeke Strand et al.   Health and Quality of Life Outcomes

Patient-reported Health-related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled Study

(2013) V. Strand et al.   JOURNAL OF RHEUMATOLOGY

Novel systemic drugs for psoriasis: Mechanism of action for apremilast, a specific inhibitor of PDE4

(2013) Peter H. Schafer et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast

(2013) Andrew Palfreeman et al.   Drug Design Development and Therapy

Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study

(2012) Georg Schett et al.   ARTHRITIS AND RHEUMATISM

Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

(2012) Arthur Kavanaugh et al.   ARTHRITIS AND RHEUMATISM

Apremilast mechanism of action and application to psoriasis and psoriatic arthritis

(2012) Peter Schafer   BIOCHEMICAL PHARMACOLOGY

Apremilast as a treatment for psoriasis

(2012) Brandon Shutty et al.   EXPERT OPINION ON PHARMACOTHERAPY

Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study

(2012) K.A. Papp et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial

(2012) Kim Papp et al.   LANCET

IL-17 receptor and its functional significance in psoriatic arthritis

(2011) Siba P. Raychaudhuri et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

(2009) PH Schafer et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cyclic AMP

(2008) Carlos H. Serezani et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY